PHILADELPHIA, Jan. 3, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at the Biotech Showcase 2012 Conference.
Dr. Mooney will make a presentation to prospective corporate partners and investors on Monday, January 9th at 2:00 PM PST. The Company's presentation will be delivered at the Parc 55 Wyndham in San Francisco.
About Biotech Showcase (Innovation – Opportunity – Collaboration)
Now in its fourth year, Biotech Showcase will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences that annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®. Public and private investors are always invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry. Visit our website for more information: www.ebdgroup.com/bts.
About Echo Therapeutics
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
For More Information:
Director, Investor Relations & Corporate Communications
|SOURCE Echo Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved